Oragenics Inc. (NYSE American: OGEN) and Sigyn Therapeutics Inc. (OTCQB: SIGY) have announced the signing of a letter of intent (LOI) under which Oragenics expects to obtain an exclusive license to develop and commercialize Sigyn’s CardioDialysis™ blood purification technology. The technology will be aimed at treating traumatic brain injury (TBI) and chronic neurodegenerative diseases, complementing Oragenics’ Phase IIa intranasal neurosteroid candidate ONP-002. This proposed dual-modality approach targets inflammation on both sides of the blood-brain barrier.
The CardioDialysis technology, developed by Sigyn, is designed to remove inflammatory mediators from the blood. By combining this with Oragenics’ intranasal delivery of ONP-002, which directly targets the brain, the company hopes to address neuroinflammation more comprehensively. According to the press release, the collaboration could lead to a first-in-class treatment for concussion and mild TBI, a significant unmet medical need.
Oragenics is a clinical-stage biotechnology company focused on brain-targeted therapeutics. Its lead candidate, ONP-002, is being developed as a potential treatment for concussion and mild TBI, with clinical trials planned in Australia and subsequent U.S. Phase 2b trials. The company’s intranasal delivery platform also has potential applications for Parkinson’s disease, Alzheimer’s disease, PTSD, and anxiety disorders.
The LOI marks a strategic expansion for Oragenics, moving beyond its core intranasal technology to incorporate a blood purification approach. For Sigyn, the deal provides a pathway to advance its CardioDialysis platform into neurological indications. The news is significant for investors as it diversifies Oragenics’ pipeline and could accelerate development timelines for treatments targeting neuroinflammation.
Full details of the press release are available at https://ibn.fm/VD4RO. For more information about Oragenics, visit oragenics.com. Updates on OGEN can be found in the company’s newsroom at https://ibn.fm/OGEN.
